PET PET
  • My Account
  • Subscribe
Become a Friend Donate
  • About Us
    • People
    • Press Office
    • Our History
  • Get Involved
    • Become a Friend of PET
    • Volunteer
    • Campaigns
    • Writing Scheme
    • Partnership and Sponsorship
    • Advertise with Us
  • Donate
    • Become a Friend of PET
  • BioNews
    • News
    • Comment
    • Reviews
    • Elsewhere
    • Topics
    • Glossary
    • Newsletters
  • Events
    • Upcoming Events
    • Previous Events
  • Engagement
    • Policy and Projects
      • Resources
    • Education
  • Jobs & Opportunities
  • Contact Us
  • About Us
    • People
    • Press Office
    • Our History
  • Get Involved
    • Become a Friend of PET
    • Volunteer
    • Campaigns
    • Writing Scheme
    • Partnership and Sponsorship
    • Advertise with Us
  • Donate
    • Become a Friend of PET
  • BioNews
    • News
    • Comment
    • Reviews
    • Elsewhere
    • Topics
    • Glossary
    • Newsletters
  • Events
    • Upcoming Events
    • Previous Events
  • Engagement
    • Policy and Projects
      • Resources
    • Education
  • Jobs & Opportunities
  • Contact Us
  • My Account
  • Subscribe
  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements
PETBioNewsNewsGene test identifies breast cancer patients who can avoid chemotherapy

BioNews

Gene test identifies breast cancer patients who can avoid chemotherapy

Published 2 October 2015 posted in News and appears in BioNews 822

Author

Dr Nikki Davis

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.

A genetic test that can identify women with early-stage breast cancer who can be spared unnecessary treatment with chemotherapy has been shown to be effective in a clinical study...

A genetic test that can identify women with early-stage breast cancer who can be spared unnecessary treatment with chemotherapy has been shown to be effective in a clinical study.

By looking at several genes in the tumour, the test — called Oncotype Dx — can assess how aggressive the disease is. This information can then be used by clinicians to help decide whether hormonal-based therapy is enough to treat the tumour or if chemotherapy is needed.

Initial data from the TAILORx trial being carried out by the US National Institutes of Health, and involving over 10,000 women with early-stage breast cancer, demonstrated that women given a low recurrence score by the test may effectively use hormone therapy alone. Patients with a recurrence score of 10 or less and receiving hormone therapy alone had a less than one percent chance of their cancer returning at five years.

'These findings will give women with early-stage breast cancer greater certainty that anti-oestrogen [hormonal] therapy will decrease their risk of recurrence and increase their chance for survival whereas chemotherapy will not,' says Dr Mary Lou Smith, a breast cancer survivor who helped design the study through her role as a leader in the ECOG-ACRIN Cancer Research Advocates Committee.

The Oncotype Dx test looks at the expression of 21 genes in the tumour. This information is used to calculate a recurrence score on a scale of 0—100 that predicts how likely it is that the breast cancer will recur; the lower the score the less aggressive the tumour is.

Although the test initially came onto the market in 2004 after being tested in archived breast-cancer tissue samples, until now the test's capability to predict whether a patient would or would not benefit from chemotherapy had not been fully evaluated in a clinical trial. 

The patients involved in the study had early-stage breast cancer, small tumours that had no mutation in the HER2 gene, and no spread of cancer to their lymph nodes. The current guidelines in the USA recommend that these women receive chemotherapy to prevent the cancer from recurring, depending on the size or grade of the tumour.

In the trial, over 1600 women with a recurrence score of 0—10 (those at low risk of their disease returning) were randomly assigned to receive hormonal therapy without chemotherapy. At five years, 98 percent were alive, and almost 94 percent remained disease free, showing that some women can be effectively treated with hormonal-based anti-cancer drugs alone.

This means that patients who might benefit from potentially life-saving chemotherapy can be identified, while those who do not need it can be spared from unnecessary treatment and the side effects that come with chemotherapy.

'What we've shown is that if you have a low recurrence score, you do really, really well with [hormone] therapy alone,' says Professor Joseph Sparano, lead author of the study and associate chairman of oncology at Montefiore Medical Center.

'The likelihood of responding to chemotherapy would be nil. So I think we can be much more confident in making the recommendation to just use [hormone] therapy alone, especially in patients where we might have been a little skittish about recommending sparing chemotherapy.'

However, the score cut off-of 10 is only arbitrary, and it is possible that women with a higher recurrence score could also avoid chemotherapy. This theory is being tested as the trial continues to monitor patients with recurrence scores between 11 and 25, a group that represents a much higher proportion of patients.

Related Articles

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
9 May 2016 • 2 minutes read

Five new risk genes unearthed in breast cancer DNA trawl

by Dr Hannah Somers

What researchers claim as the largest-ever whole-genome sequencing study in breast cancer has revealed five previously unidentified genes which drive the development of the disease...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
11 January 2016 • 2 minutes read

Twin study finds that cancer is 33 percent heritable

by Dr Lucy Freem

A study involving more than 200,000 Nordic twins has found that cancer is 33 percent heritable...

Image by Alan Handyside via the Wellcome Collection. Depicts a human egg soon after fertilisation, with the two parental pronuclei clearly visible.
CC0 1.0
Image by Alan Handyside via the Wellcome Collection. Depicts a human egg soon after fertilisation, with the two parental pronuclei clearly visible.
News
30 November 2015 • 1 minute read

Obamacare may have boosted fertility-sparing cervical cancer treatment

by Dr Mary Yarwood

More young women in the USA with cervical cancer are having fertility-sparing treatment due to earlier diagnosis...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
9 November 2015 • 1 minute read

Liquid biopsy could track cancer progress in real time

by Ayala Ochert

Scientists say it may be possible to track the progress of cancer — and cancer treatment — in real time from fragments of tumour DNA that are shed into the bloodstream...

Image by Alan Handyside via the Wellcome Collection. Depicts a human egg soon after fertilisation, with the two parental pronuclei clearly visible.
CC0 1.0
Image by Alan Handyside via the Wellcome Collection. Depicts a human egg soon after fertilisation, with the two parental pronuclei clearly visible.
News
23 October 2015 • 2 minutes read

Stem cells show potential to restore fertility after chemotherapy

by Dr Nicoletta Charolidi

A stem-cell therapy in mice shows promise for reversing infertility in women who have received cancer treatment...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
25 September 2015 • 2 minutes read

Mutations may predict breast cancer relapse

by Neil Stoker

Researchers have identified genetic differences in breast cancers that relapse and those that do not, suggesting that the finding could be used to help doctors identify patients most at risk of their cancer returning...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
28 August 2015 • 2 minutes read

Blood test predicts breast cancer relapse

by Dr Hannah Somers

Scientists have developed a blood test that can predict several months in advance which breast cancer patients will relapse.

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
6 February 2015 • 3 minutes read

Breast cancer recurrence gene test gets NHS go-ahead

by Dr Molly Godfrey

A genetic test to estimate the chance of breast cancer recurrence after surgery is set to become more widely available on the NHS....

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
27 September 2013 • 3 minutes read

Gene test to determine breast cancer treatment gets approval

by David Gerard O'Rourke

A new genetic test that can estimate the risk of breast cancer in women returning after surgery has been approved for use in the NHS....

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
19 April 2013 • 2 minutes read

'Gene signature' predicts chemotherapy survival

by Siobhan Chan

Scientists have identified an eight-gene 'signature' that can predict patients' response to chemotherapy...

Leave a Reply Cancel reply

You must be logged in to post a comment.

« New CRISPR technique could improve precision

Data-Label The UK's Leading Supplier Of Medical Labels & Asset Labels

RetiringDentist.co.uk The UK's Leading M&A Company.

Find out how you can advertise here
easyfundraising
amazon

This month in BioNews

  • Popular
  • Recent
13 June 2022 • 2 minutes read

Drop in diversity of blood stem cells leads to old-age health issues

1 August 2022 • 2 minutes read

First UK medical guidelines issued for trans fertility preservation

1 August 2022 • 2 minutes read

Common virus may be cause of recent hepatitis cases in children

1 August 2022 • 2 minutes read

Male age has more impact on IVF birth rate than previously thought

1 August 2022 • 2 minutes read

CRISPR genome editing treatments may raise cancer risk

1 August 2022 • 2 minutes read

Differences in IVF-conceived children's size disappear by adolescence

Subscribe to BioNews and other PET updates for free.

Subscribe
  • Twitter
  • Facebook
  • Instagram
  • LinkedIn
  • YouTube
  • RSS
Wellcome
Website redevelopment supported by Wellcome.

Website by Impact Media Impact Media

  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements

© 1992 - 2022 Progress Educational Trust. All rights reserved.

Limited company registered in England and Wales no 07405980 • Registered charity no 1139856

Subscribe to BioNews and other PET updates for free.

Subscribe
PET PET

PET is an independent charity that improves choices for people affected by infertility and genetic conditions.

  • Twitter
  • Facebook
  • Instagram
  • LinkedIn
  • YouTube
  • RSS
Wellcome
Website redevelopment supported by Wellcome.

Navigation

  • About Us
  • Get Involved
  • Donate
  • BioNews
  • Events
  • Engagement
  • Jobs & Opportunities
  • Contact Us

BioNews

  • News
  • Comment
  • Reviews
  • Elsewhere
  • Topics
  • Glossary
  • Newsletters

Other

  • My Account
  • Subscribe

Website by Impact Media Impact Media

  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements

© 1992 - 2022 Progress Educational Trust. All rights reserved.

Limited company registered in England and Wales no 07405980 • Registered charity no 1139856